BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 29481579)

  • 1. Loss of Full-Length GATA1 Expression in Megakaryocytes Is a Sensitive and Specific Immunohistochemical Marker for the Diagnosis of Myeloid Proliferative Disorder Related to Down Syndrome.
    Lee WY; Weinberg OK; Evans AG; Pinkus GS
    Am J Clin Pathol; 2018 Mar; 149(4):300-309. PubMed ID: 29481579
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pluripotent stem cell model of early hematopoiesis in Down syndrome reveals quantitative effects of short-form GATA1 protein on lineage specification.
    Matsuo S; Nishinaka-Arai Y; Kazuki Y; Oshimura M; Nakahata T; Niwa A; Saito MK
    PLoS One; 2021; 16(3):e0247595. PubMed ID: 33780474
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Modeling Down Syndrome Myeloid Leukemia by Sequential Introduction of
    Barwe SP; Sebastian A; Sidhu I; Kolb EA; Gopalakrishnapillai A
    Cells; 2022 Feb; 11(4):. PubMed ID: 35203280
    [TBL] [Abstract][Full Text] [Related]  

  • 4. GATA1 Is a Sensitive and Specific Nuclear Marker for Erythroid and Megakaryocytic Lineages.
    Lee WY; Weinberg OK; Pinkus GS
    Am J Clin Pathol; 2017 Apr; 147(4):420-426. PubMed ID: 28340113
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A unique role of GATA1s in Down syndrome acute megakaryocytic leukemia biology and therapy.
    Xavier AC; Edwards H; Dombkowski AA; Balci TB; Berman JN; Dellaire G; Xie C; Buck SA; Matherly LH; Ge Y; Taub JW
    PLoS One; 2011; 6(11):e27486. PubMed ID: 22110660
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transient abnormal myelopoiesis in non-Down syndrome neonate.
    Ohkawa T; Miyamoto S; Sugie M; Tomizawa D; Imai K; Nagasawa M; Morio T; Mizutani S; Takagi M
    Pediatr Int; 2015; 57(1):e14-7. PubMed ID: 25711269
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A sensitive and inexpensive high-resolution melting-based testing algorithm for diagnosis of transient abnormal myelopoiesis and myeloid leukemia of Down syndrome.
    Camargo R; de Castro Moreira Dos Santos A; Cândido Guido B; Lemos Mendanha Cavalcante L; Silva Dias AC; Mendonça de Pontes R; Magalhães Furtado F; Feitosa Salviano C; Tiziani V; Martins Córdoba JC; Quezado Magalhães IM
    Pediatr Blood Cancer; 2022 Nov; 69(11):e29866. PubMed ID: 35731576
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Transient Abnormal Myelopoiesis and AML in Down Syndrome: an Update.
    Bhatnagar N; Nizery L; Tunstall O; Vyas P; Roberts I
    Curr Hematol Malig Rep; 2016 Oct; 11(5):333-41. PubMed ID: 27510823
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Naturally occurring oncogenic GATA1 mutants with internal deletions in transient abnormal myelopoiesis in Down syndrome.
    Toki T; Kanezaki R; Kobayashi E; Kaneko H; Suzuki M; Wang R; Terui K; Kanegane H; Maeda M; Endo M; Mizuochi T; Adachi S; Hayashi Y; Yamamoto M; Shimizu R; Ito E
    Blood; 2013 Apr; 121(16):3181-4. PubMed ID: 23440243
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Transient abnormal myelopoiesis of a newborn not associated with chromosome 21 abnormalities or GATA1 mutations.
    Nakashima MO; Shetty S; Chicka M; Flagg A; Eng C; Cotta CV
    Pediatr Blood Cancer; 2015 Feb; 62(2):353-355. PubMed ID: 25175265
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PRAME immunohistochemical staining in transient abnormal myelopoiesis and myeloid leukemia associated with Down syndrome.
    Chisholm KM; Rivetta CV; Heerema-McKenney A
    Ann Clin Lab Sci; 2015; 45(2):121-7. PubMed ID: 25887863
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mutations in exon 2 of GATA1 are early events in megakaryocytic malignancies associated with trisomy 21.
    Rainis L; Bercovich D; Strehl S; Teigler-Schlegel A; Stark B; Trka J; Amariglio N; Biondi A; Muler I; Rechavi G; Kempski H; Haas OA; Izraeli S
    Blood; 2003 Aug; 102(3):981-6. PubMed ID: 12649131
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mechanisms of Progression of Myeloid Preleukemia to Transformed Myeloid Leukemia in Children with Down Syndrome.
    Labuhn M; Perkins K; Matzk S; Varghese L; Garnett C; Papaemmanuil E; Metzner M; Kennedy A; Amstislavskiy V; Risch T; Bhayadia R; Samulowski D; Hernandez DC; Stoilova B; Iotchkova V; Oppermann U; Scheer C; Yoshida K; Schwarzer A; Taub JW; Crispino JD; Weiss MJ; Hayashi Y; Taga T; Ito E; Ogawa S; Reinhardt D; Yaspo ML; Campbell PJ; Roberts I; Constantinescu SN; Vyas P; Heckl D; Klusmann JH
    Cancer Cell; 2019 Aug; 36(2):123-138.e10. PubMed ID: 31303423
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Placental Pathology in Down Syndrome-Associated Transient Abnormal Myelopoiesis.
    Kuo E; Kumarapeli AR
    Arch Pathol Lab Med; 2020 Mar; 144(3):388-393. PubMed ID: 30969155
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oncogenic Gata1 causes stage-specific megakaryocyte differentiation delay.
    Juban G; Sakakini N; Chagraoui H; Cruz Hernandez D; Cheng Q; Soady K; Stoilova B; Garnett C; Waithe D; Otto G; Doondeea J; Usukhbayar B; Karkoulia E; Alexiou M; Strouboulis J; Morrissey E; Roberts I; Porcher C; Vyas P
    Haematologica; 2021 Apr; 106(4):1106-1119. PubMed ID: 32527952
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Transient leukemia in a newborn without Down syndrome: case report and review of the literature.
    Rozen L; Huybrechts S; Dedeken L; Heijmans C; Dessars B; Heimann P; Lambert F; Noubouossie DF; Ferster A; Demulder A
    Eur J Pediatr; 2014 Dec; 173(12):1643-7. PubMed ID: 24253371
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Myeloid proliferations related to Down syndrome].
    Hasegawa D
    Rinsho Ketsueki; 2019; 60(9):1299-1307. PubMed ID: 31597856
    [TBL] [Abstract][Full Text] [Related]  

  • 18. GATA1 mutations in a cohort of Malaysian children with Down syndrome-associated myeloid disorder.
    Lum SH; Choong SS; Krishnan S; Mohamed Z; Ariffin H
    Singapore Med J; 2016 Jun; 57(6):320-4. PubMed ID: 27353457
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sensitive detection of GATA1 mutations using complementary DNA-based analysis for transient abnormal myelopoiesis associated with the Down syndrome.
    Mizuta S; Yamane N; Mononobe S; Watanabe A; Kitamura R; Takahara T; Matsushima C; Yoshida A; Okamoto S; Tanaka K; Iwai A; Ikegawa A; Wada T; Usami I; Maihara T; Komai T; Heike T; Nishida Y; Kobayashi K
    Int J Lab Hematol; 2022 Apr; 44(2):349-355. PubMed ID: 34761527
    [TBL] [Abstract][Full Text] [Related]  

  • 20. GATA1 and cooperating mutations in myeloid leukaemia of Down syndrome.
    Garnett C; Cruz Hernandez D; Vyas P
    IUBMB Life; 2020 Jan; 72(1):119-130. PubMed ID: 31769932
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.